TYK2
44 programs · 44 companies
Programs
44
Companies
44
Active Trials
39
Targeting TYK2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | PV | |
| MRK-3732 | Merck & Co | Phase 1 | Ewing Sarcoma | |
| COR-9566 | Corcept | Approved | Cervical CaHemophilia A | |
| SND-9531 | Syndax | Phase 3 | MelanomaMigraine | |
| RAR-1117 | Ultragenyx | Phase 1/2 | WMEndometrial Ca | |
| Datocilimab | Neumora | Phase 1 | NSCLCPsoriasis | |
| Polaglumide | Foghorn | Phase 3 | SMACML | |
| Olpatenlimab | Absci | Phase 3 | PBC | |
| RDY-9256 | Dr Reddy's | Phase 1/2 | FL | |
| Rimainavolisib | Otsuka | Phase 3 | GAMelanoma | |
| DAN-IIT-515 | Dana-Farber | Preclinical | AML | |
| GUS-IIT-540 | Gustave Roussy | Phase 1/2 | Dravet | |
| XTA-2008 | XtalPi | Preclinical | CeliacACC | |
| ASM-5108 | Assembly Bio | Phase 1 | PsoriasisFabry | |
| Capilucimab | Kartos Ther | Phase 3 | Bladder Ca | |
| FOR-9610 | Forma Therapeutics | Phase 2 | NBSCLC | |
| Teravorutinib | Neumedicines | Phase 1/2 | CLL | |
| Zoricapivasertib | BioSig Technologies | Phase 3 | Huntington's | |
| Lirarasimod | HTG Molecular | Phase 1/2 | T2DAS | |
| Pemiratamab | ARS Pharma | Phase 2/3 | WMIPF | |
| 601-209 | Shanghai Pharma | Phase 2/3 | ALSEwing Sarcoma | |
| Terafutibatinib | Retrophin (Zevra) | Phase 2/3 | PAH | |
| MOM-980 | Momenta (J&J) | Preclinical | TTR AmyloidosisDMD | |
| Zanutuximab | BigHat Bio | Phase 2 | GBMWilms | |
| CHR-2584 | Chroma Med | Phase 2 | Psoriasis | |
| EVO-1057 | Evommune | Phase 3 | Huntington'sT2D | |
| FRE-IIT-864 | Fred Hutch | Phase 2 | Bladder Ca | |
| Voxafutibatinib | Travere Ther | Phase 1 | SMAMigraine | |
| MIM-1147 | Mimetogen | Phase 2 | AngelmanNB | |
| Riboosocimab | StrideBio | Phase 2 | PVAsthma | |
| RNA-7525 | Avidity Bio | Phase 2/3 | MelanomaEndometrial Ca | |
| KIA-7239 | Kiadis (Sanofi) | Phase 2/3 | T2DDLBCL | |
| PAC-8776 | Pacific Biosciences | Preclinical | RettFL | |
| Kemazanubrutinib | Xeris Biopharma | Phase 1/2 | NarcolepsyRB | |
| Cevirelsin | Divi's Laboratories | Phase 2 | AMLBladder Ca | |
| Teratenlimab | Aarti Drugs | Preclinical | PTSDFSGS | |
| MAN-5524 | Mankind Pharma | Phase 2 | MM | |
| PRO-2782 | Probiomed | Preclinical | T2DSchizophrenia | |
| Fixalucimab | Neopharma | Preclinical | WilmsCRC | |
| KIN-IIT-683 | King Faisal Spec Hosp | Phase 2 | MCC | |
| HET-7567 | Hetero Drugs | Phase 2 | RSVRB | |
| Tiratapinarof | CTTQ Pharma | Phase 3 | PTSDDravet | |
| Surainavolisib | Lee's Pharm | NDA/BLA | MCL | |
| Fixaratamab | SK Biopharm | Approved | Endometrial Ca |